H.R. 4780 119th Congress House

USTRx Act

Official title: To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based poli… Show full official titleShow less

Introduced: July 29, 2025 Introduced by: Jodey C. Arrington Republican · Texas See on congress.gov

Foreign Trade and International Finance

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jul 29, 2025

Referred to the House Committee on Ways and Means.

Jul 29, 2025

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now July 29, 2025

Referred to the House Committee on Ways and Means.

Plain-English summary Congressional Research Service

Use Sovereignty To reduce Rx Act or the USTRx Act

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

Bill text 1 version

Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Ways and Means Committee
House of Representatives

Lobbying activity 12

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
GSK (FKA GLAXOSMITHKLINE INC.)
for GSK (FKA GLAXOSMITHKLINE INC.) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
COUNCIL FOR INNOVATION PROMOTION (C4IP)
for COUNCIL FOR INNOVATION PROMOTION (C4IP) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
ALKERMES, INC.
for ALKERMES, INC. · Massachusetts · 3rd Quarter 2026 (July 1 - Sep 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)
COUNCIL FOR INNOVATION PROMOTION (C4IP)
for COUNCIL FOR INNOVATION PROMOTION (C4IP) · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)

Bodies those filers lobbied

HOUSE OF REPRESENTATIVES
12 filings
SENATE
12 filings
Centers For Medicare and Medicaid Services (CMS)
10 filings
Health & Human Services, Dept of (HHS)
10 filings
Patent & Trademark Office (PTO)
8 filings
Executive Office of the President (EOP)
4 filings
Office of Management & Budget (OMB)
4 filings
U.S. Trade Representative (USTR)
4 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 12 filings →

Cosponsors 8